{"title":"氟化4-甲基二恶唑烷-5- 1:合成及诱导细胞凋亡的抗增殖活性","authors":"Zi-Han Li, Ya Han, Yi-Chao Li, Xue-Qiong Zhang, Subarna Jyoti Kalita, Yi-Yong Huang","doi":"10.1021/acsmedchemlett.6c00344","DOIUrl":null,"url":null,"abstract":"<p>Sesquiterpene lactones, featuring an α-methylene-γ-lactone\r\nmoiety, serve as lead compounds for anticancer drug development. Their\r\nnitrogen-containing analogues, namely, 4-methylideneisoxazolidin-5-ones,\r\nhave attracted special attention for their promising anticancer properties.\r\nInstalling a fluorine atom at the exocyclic double bond of these analogues\r\nis highly desirable for improving metabolic stability, bioavailability,\r\nand lipophilicity, yet this has not been achieved to date due to the\r\nlack of an efficient synthetic method, representing a major obstacle\r\nin drug development. Herein, we report a Ni(II)-catalyzed [3 + 2]\r\ncycloaddition/rearrangement cascade reaction of <em>gem</em>-difluorocyclopropenyl imides and <em>N</em>-Bn nitrones,\r\nproviding direct access to (<em>Z</em>)-4-(monofluoroalkylidene)isoxazolidin-5-ones\r\nin good to high yields. The compounds <strong>3aw</strong> and <strong>3as</strong> show promising <em>in vitro</em> antiproliferative activity\r\nagainst mouse mammary carcinoma 4T1 cells (IC<sub>50</sub> = 6.85\r\n± 0.43 μM) and human lung carcinoma A549 cells (IC<sub>50</sub> = 10.34 ± 0.07 μM), respectively. Mechanistic\r\nstudies reveal that the activity occurs via a mitochondria-mediated\r\nintrinsic apoptotic pathway.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"17 10","pages":"2219–2229"},"PeriodicalIF":3.9000,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fluorinated 4-Methylideneisoxazolidin-5-ones: Synthesis and Apoptosis-Inducing Antiproliferative Activity\",\"authors\":\"Zi-Han Li, Ya Han, Yi-Chao Li, Xue-Qiong Zhang, Subarna Jyoti Kalita, Yi-Yong Huang\",\"doi\":\"10.1021/acsmedchemlett.6c00344\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Sesquiterpene lactones, featuring an α-methylene-γ-lactone\\r\\nmoiety, serve as lead compounds for anticancer drug development. Their\\r\\nnitrogen-containing analogues, namely, 4-methylideneisoxazolidin-5-ones,\\r\\nhave attracted special attention for their promising anticancer properties.\\r\\nInstalling a fluorine atom at the exocyclic double bond of these analogues\\r\\nis highly desirable for improving metabolic stability, bioavailability,\\r\\nand lipophilicity, yet this has not been achieved to date due to the\\r\\nlack of an efficient synthetic method, representing a major obstacle\\r\\nin drug development. Herein, we report a Ni(II)-catalyzed [3 + 2]\\r\\ncycloaddition/rearrangement cascade reaction of <em>gem</em>-difluorocyclopropenyl imides and <em>N</em>-Bn nitrones,\\r\\nproviding direct access to (<em>Z</em>)-4-(monofluoroalkylidene)isoxazolidin-5-ones\\r\\nin good to high yields. The compounds <strong>3aw</strong> and <strong>3as</strong> show promising <em>in vitro</em> antiproliferative activity\\r\\nagainst mouse mammary carcinoma 4T1 cells (IC<sub>50</sub> = 6.85\\r\\n± 0.43 μM) and human lung carcinoma A549 cells (IC<sub>50</sub> = 10.34 ± 0.07 μM), respectively. Mechanistic\\r\\nstudies reveal that the activity occurs via a mitochondria-mediated\\r\\nintrinsic apoptotic pathway.</p>\",\"PeriodicalId\":20,\"journal\":{\"name\":\"ACS Medicinal Chemistry Letters\",\"volume\":\"17 10\",\"pages\":\"2219–2229\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2026-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Medicinal Chemistry Letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsmedchemlett.6c00344\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/9/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsmedchemlett.6c00344","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Fluorinated 4-Methylideneisoxazolidin-5-ones: Synthesis and Apoptosis-Inducing Antiproliferative Activity
Sesquiterpene lactones, featuring an α-methylene-γ-lactone
moiety, serve as lead compounds for anticancer drug development. Their
nitrogen-containing analogues, namely, 4-methylideneisoxazolidin-5-ones,
have attracted special attention for their promising anticancer properties.
Installing a fluorine atom at the exocyclic double bond of these analogues
is highly desirable for improving metabolic stability, bioavailability,
and lipophilicity, yet this has not been achieved to date due to the
lack of an efficient synthetic method, representing a major obstacle
in drug development. Herein, we report a Ni(II)-catalyzed [3 + 2]
cycloaddition/rearrangement cascade reaction of gem-difluorocyclopropenyl imides and N-Bn nitrones,
providing direct access to (Z)-4-(monofluoroalkylidene)isoxazolidin-5-ones
in good to high yields. The compounds 3aw and 3as show promising in vitro antiproliferative activity
against mouse mammary carcinoma 4T1 cells (IC50 = 6.85
± 0.43 μM) and human lung carcinoma A549 cells (IC50 = 10.34 ± 0.07 μM), respectively. Mechanistic
studies reveal that the activity occurs via a mitochondria-mediated
intrinsic apoptotic pathway.
期刊介绍:
ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to:
Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics)
Biological characterization of new molecular entities in the context of drug discovery
Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc.
Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry
Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources
Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response
Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic
Mechanistic drug metabolism and regulation of metabolic enzyme gene expression
Chemistry patents relevant to the medicinal chemistry field.